- Home
- ALDX vs LCTX Comparison
ALDX vs LCTX Comparison
Compare ALDX & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALDX
- LCTX
- Stock Information
- Founded
- ALDX 2004
- LCTX 1990
- Country
- ALDX United States
- LCTX United States
- Employees
- ALDX N/A
- LCTX N/A
- Industry
- ALDX Biotechnology: Pharmaceutical Preparations
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALDX Health Care
- LCTX Health Care
- Exchange
- ALDX Nasdaq
- LCTX Nasdaq
- Market Cap
- ALDX 342.3M
- LCTX 274.0M
- IPO Year
- ALDX 2014
- LCTX N/A
- Fundamental
- Price
- ALDX $5.39
- LCTX $1.34
- Analyst Decision
- ALDX Strong Buy
- LCTX Strong Buy
- Analyst Count
- ALDX 2
- LCTX 4
- Target Price
- ALDX $9.50
- LCTX $4.25
- AVG Volume (30 Days)
- ALDX 772.4K
- LCTX 1.6M
- Earning Date
- ALDX 11-06-2025
- LCTX 08-12-2025
- Dividend Yield
- ALDX N/A
- LCTX N/A
- EPS Growth
- ALDX N/A
- LCTX N/A
- EPS
- ALDX N/A
- LCTX N/A
- Revenue
- ALDX N/A
- LCTX $10,914,000.00
- Revenue This Year
- ALDX N/A
- LCTX N/A
- Revenue Next Year
- ALDX $43.00
- LCTX $178.80
- P/E Ratio
- ALDX N/A
- LCTX N/A
- Revenue Growth
- ALDX N/A
- LCTX 76.43
- 52 Week Low
- ALDX $1.14
- LCTX $0.37
- 52 Week High
- ALDX $7.20
- LCTX $1.42
- Technical
- Relative Strength Index (RSI)
- ALDX 45.98
- LCTX 64.60
- Support Level
- ALDX $5.48
- LCTX $1.20
- Resistance Level
- ALDX $5.88
- LCTX $1.28
- Average True Range (ATR)
- ALDX 0.27
- LCTX 0.07
- MACD
- ALDX -0.07
- LCTX 0.00
- Stochastic Oscillator
- ALDX 1.87
- LCTX 69.64
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.